Proteins and Peptides

27 Mar 2017 Synergy Pharmaceuticals Submits Supplemental New Drug Application (sNDA) for TRULANCE™ (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
27 Mar 2017 ERYTECH Reports Positive Phase 2b Data for eryaspase for the Treatment of Metastatic Pancreatic Cancer
24 Mar 2017 EPREX® (epoetin alfa) Marketing Authorisation Extended to Include Treatment of Symptomatic Anaemia in Patients with Low or Intermediate-1-Risk Myelodysplastic Syndromes
24 Mar 2017 CHMP provides positive opinion for EU label update for Novo Nordisk's Tresiba® based on data from SWITCH trials
24 Mar 2017 Novo Nordisk receives positive opinion from the European regulatory authorities for Refixia® (nonacog beta pegol, N9-GP) for the treatment of haemophilia B
22 Mar 2017 Cue Biopharma Announces Selection of Lead Candidate Cue-101 Targeting Human Papillomavirus (HPV)-Associated Cancers
22 Mar 2017 Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
21 Mar 2017 WntResearch Announces Positive Results From Clinical Study With Drug Candidate Foxy-5
20 Mar 2017 BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment
16 Mar 2017 Shire Receives European Approval for Label Extension of CINRYZE®▼(C1 inhibitor ) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE
16 Mar 2017 Helmsley Charitable Trust and Akston Biosciences Corporation Announce Partnership to Advance Novel Technology to Treat Type 1 Diabetes
14 Mar 2017 Lung Therapeutics, Inc. Doses First Patient in Phase 1 Clinical Trial of LTI-01 in Australia and New Zealand
09 Mar 2017 ProtoKinetix Announces Start of Phase 1 & Phase 2 Clinical Trials for the use of AAGP™ PKX-001 Treated Islet Cells in the Treatment of Type 1 Diabetes
07 Mar 2017 Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines
04 Mar 2017 Amgen Presents Overall Survival Data From KYPROLIS® (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop
04 Mar 2017 FDA approves first treatment for frequent urination at night due to overproduction of urine
03 Mar 2017 BIOCAD: The first ever biosimilar of interferon beta-1a approved in Russia
02 Mar 2017 Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study
01 Mar 2017 Phase 3 Head-to-Head Trial Showed KYPROLIS® (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade® (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients
01 Mar 2017 Recombinant clotting factor VIII with the name Vihuma® approved
28 Feb 2017 RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.
28 Feb 2017 La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501
21 Feb 2017 CohBar, Inc. Announces Positive Results from Preclinical NASH Study of its Lead Drug Candidates
20 Feb 2017 AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada
20 Feb 2017 Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing